Biovail faces possible FDA hitch to pain drug
Article Abstract:
The US Food and Drug Administration that has asked Biovail Corp. for more clinical information about its blockbuster pain reliever, is reported. The Mississauga-based company has not disclosed what else it has to submit to the agency for final approval of its Ralivia ER drug.
Publisher: Bell Globemedia Interactive
Publication Name: Globe & Mail (Toronto, Canada)
Subject: News, opinion and commentary
ISSN: 0319-0714
Year: 2004
Product information, Medicinal and Botanical Manufacturing, Medicinals and botanicals, Analgesics & Antipyretics NEC, United States. Food and Drug Administration, Analgesics, Biovail Corp.
Publication Name: Globe & Mail (Toronto, Canada)
Subject: News, opinion and commentary
ISSN: 0319-0714
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
QLT plans $104-million stock buyback
Article Abstract:
The impact of second quarter 2006 profit downfall for QLT Inc., which proposes $104 million stock buyback, is discussed.
Publisher: Bell Globemedia Interactive
Publication Name: Globe & Mail (Toronto, Canada)
Subject: News, opinion and commentary
ISSN: 0319-0714
Year: 2006
Sales, profits & dividends, Securities issued, listed, Securities, Company sales and earnings, Company earnings/profit, Company securities, QLT Inc., QLT
Publication Name: Globe & Mail (Toronto, Canada)
Subject: News, opinion and commentary
ISSN: 0319-0714
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
Subjects list: Canada, Pharmaceutical industry
Similar abstracts:
- Abstracts: Biovail reduces quarterly guidance. FDA's tramadol decision boosts Biovail outlook. Biovail beats investor anxiety
- Abstracts: KGB cover-up spooks security alliance. Skittling the lickspittles. Turf war strategies
- Abstracts: Road red. Advance Australia card. Survival of the fittest
- Abstracts: Virtual realty. Rent buoys
- Abstracts: Hollinger board scheduled to meet. Versus to underwrite stock issues. Hollinger subsidiary to review Black deal: Forms committee to consider its options
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.